Navigation Links
AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
Date:2/13/2009

Top Global Pharmaceutical Company Integrates Their Clinical Data System (CDS) and East(R) for Improved Clinical Data Handling and Trial Analysis

CAMBRIDGE, Mass., Feb. 13 /PRNewswire/ -- Cytel Inc. today announced that AstraZeneca International has expanded their deployment of Cytel's East(R) software, the most widely-used clinical trial design, simulation and monitoring system available. AstraZeneca's increased use of East(R) also features automated data transfer between their CDS and East's trial monitoring component. By eliminating manual data entry, AstraZeneca achieved the multiple benefits of greater clinical trial analysis efficiency and increased security of vital study data.

Cytel Vice President of Business Development, Steve Herbert, recalled the initial request: "AstraZeneca came to Cytel looking to improve data entry into East(R) from their own Clinical Data System (CDS). Our software engineers worked closely with their AstraZeneca's counterparts to help achieve far more efficient data handling within their CDS path and ensure compliance with Clinical Data Interchange Standards Consortium (CDISC) guidelines."

Maria Johansson, Business Tools Manager at AstraZeneca praised Cytel's response saying, "Cytel's customized version of East(R) for AstraZeneca is now fully integrated with our clinical data system eliminating any manual data handling and better facilitating the data analysis process. This new automation also helps us maintain the integrity of the interim data, reducing the risk of unintentional un-blinding."

Of the experience, Mrs. Johansson remarked, "The cooperation between AstraZeneca and Cytel has been very good. We're very pleased with the outcome."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

About Cytel

Cytel Inc. is a leading provider of clinical trial design services and specialized statistical software for the biopharmaceutical, medical device, academic, and government research markets. Cytel's East(R) system is used at hundreds of commercial sites, throughout academia and by regulators to design, simulate and monitor adaptive and group sequential clinical trials. Cytel provides trial sponsors with innovative tools, training and consultation to increase the return on investment in clinical development.


'/>"/>
SOURCE Cytel Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
2. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
3. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
4. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
5. Melior Enters Research Collaboration with AstraZeneca
6. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
7. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
8. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
9. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
10. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
11. AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):